LOMOTIL (diphenoxylate hydrochloride and atropine sulfate) by Pfizer is clinical pharmacology diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood. First approved in 1960.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
LOMOTIL is an oral small-molecule antidiarrheal combining diphenoxylate hydrochloride and atropine sulfate, approved in 1960. It reduces diarrhea by enhancing segmentation and prolonging gastrointestinal transit time through direct effects on bowel smooth muscle. The drug is indicated for symptomatic relief of acute and chronic diarrhea in patients who require pharmacologic management.
As a mature product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely consolidating and preparing for generic erosion rather than expanding.
CLINICAL PHARMACOLOGY Diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood. After a 5 mg oral dose of carbon-14 labeled diphenoxylate hydrochloride in ethanolic solution…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on LOMOTIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on LOMOTIL offers limited career growth potential given its mature lifecycle stage and approaching loss of exclusivity, with zero linked job openings currently. This assignment is better suited for pharmaceutical professionals seeking stability in a legacy product or those transitioning toward regulatory or market access specializations rather than career advancement.